Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Elesclomol sodium; STA-4783

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synta Pharmaceuticals
  • Class Antineoplastics; Hydrazines; Ketones; Small molecules; Thiones
  • Mechanism of Action Apoptosis stimulants; Chelating agents; HSP70 heat shock protein stimulants; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 15 Mar 2016 Synta Pharmaceuticals enter into an asset purchase agreement with a third party (Synta Pharmaceuticals, Form 10-K, March 2016)
  • 13 Aug 2015 Elesclomol is still in phase II trials for Ovarian cancer (Combination therapy, Second-line therapy or greater) in the USA
  • 09 Apr 2014 Discontinued - Phase-I for Prostate cancer (combination therapy, hormone refractory, late-stage disease, metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top